• 1
    Van Vollenhoven RF, Keystone EC, Furie R, Blesch A, Wang C, Curtis JR. Gastrointestinal safety in patients with rheumatoid arthritis treated with tocilizumab: data from Roche clinical trials [abstract]. Arthritis Rheum 2009; 60 Suppl: S602.
  • 2
    Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, et al, on behalf of the British Society for Rheumatology Biologics Register. Serious infection following anti–tumor necrosis factor α therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum 2007; 56: 2896904.
  • 3
    Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 91520.
  • 4
    Curtis J, Chen S, Werther W, John A, Johnson D. Validation of ICD-9-CM to identify GI perforation in administrative claims data among rheumatoid arthritis patients [abstract]. Pharmacoepidemiol Drug Saf 2010; 19 Suppl 1: S58.
  • 5
    Rothman KJ. Epidemiology. New York: Oxford University Press; 2002.
  • 6
    Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991; 115: 78796.
  • 7
    Fries JF, Williams CA, Bloch DA, Michel BA. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1991; 91: 21322.
  • 8
    Food and Drug Administration. Safety update on TNF-α antagonists: infliximab and etanercept. URL:
  • 9
    Sihvonen S, Korpela M, Mustonen J, Huhtala H, Karstila K, Pasternack A. Mortality in patients with rheumatoid arthritis treated with low-dose oral glucocorticoids: a population-based cohort study. J Rheumatol 2006; 33: 17406.
  • 10
    Curtis JR, Jain A, Askling J, Bridges SL Jr, Carmona L, Dixon W, et al. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum 2010; 40: 2-14.e1.
  • 11
    Fraenkel L, Bogardus S, Concato J, Felson D. Risk communication in rheumatoid arthritis. J Rheumatol 2003; 30: 4438.
  • 12
    Fraenkel L, Bogardus S, Concato J, Felson D. Unwillingness of rheumatoid arthritis patients to risk adverse effects. Rheumatology (Oxford) 2002; 41: 25361.
  • 13
    Hernandez-Diaz S, Rodriguez LA. Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies. J Clin Epidemiol 2002; 55: 15763.
  • 14
    Morris CR, Harvey IM, Stebbings WS, Hart AR. Incidence of perforated diverticulitis and risk factors for death in a UK population. Br J Surg 2008; 95: 87681.
  • 15
    Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003; 124: 28892.
  • 16
    Lanas A, Garcia-Rodriguez LA, Polo-Tomas M, Ponce M, Alonso-Abreu I, Perez-Aisa MA, et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol 2009; 104: 163341.
  • 17
    Wolfe F, Hawley DJ. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients. J Rheumatol 2000; 27: 166873.